Psoriasis Club
  • Forum
  • Home
  • Portal
  • Member List
  • Psoriasis Score
  • PQOLS
  • What is psoriasis
  • Search
  • Help
Hello Guest, Welcome To The Psoriasis Club Forum. We are a self funded friendly group of people who understand.
Never be alone with psoriasis, come and join us. (Members see a lot more than you)
wave
Login Register
Login
Username:
Password:
Lost Password?
 
Psoriasis Club › HealthHealth Boards › Psoriasis In The News v
« Previous 1 2 3 4 5 … 54 Next »

Cosentyx and erosion progression in psoriatic arthritis

Threaded Mode
Cosentyx and erosion progression in psoriatic arthritis
Fred Online
I Wanted To Change the World But Got Up Far Too Late.
Moderator
Posts: 66,944
Threads: 3,888
Joined: Aug 2011
Gender: Male
Location: France
Psoriatic Arthritis Score: 1
PQOLS: 1
Treatment: Bimzelx / Coconut Oil
#1
News  Fri-14-03-2025, 12:03 PM
Results of a one-year  trial utilising high-resolution peripheral quantitative computed tomography in patients with psoriatic arthritis using Cosentyx (secukinumab).

Quote:
Objectives:
This study aimed to ascertain the effect of secukinumab on erosion and enthesiophyte progression in psoriatic arthritis (PsA) by high-resolution peripheral quantitative computed tomography (HR-pQCT).

Methods:
This was a phase 4, double-blind, randomized, placebo-controlled trial. Patients with active PsA and ≥ 1 erosion in the metacarpophalangeal joints (MCPJ) 2-4 were randomised in a 1:1 ratio to subcutaneous secukinumab or placebo. HR-pQCT of the MCPJ 2-4 were performed at baseline, week 24 and week 48 The primary outcome was the changes in the volume of erosions on MCPJ 2-4 measured by HR-pQCT at 24 and 48 weeks.

Results:
Forty patients (age: 51.9±13.4 years, 20 [50%] male, disease duration: 4.7±6.7years) were recruited. Thirty-four patients who completed study treatment were included in the per-protocol analysis. At baseline, week 24 and week 48, the secukinumab group showed a significant reduction in erosion volume, whereas no changes were observed in the placebo group (change in the secukinumab group: -0.1 (-0.5, 0.0) vs: 0.0 (-0.2, 0.4) in the placebo group, p=0.004). A similar trend was observed for enthesiophyte volume changes in the secukinumab group, while no differences were noted in the placebo group (change in the secukinumab group: -0.1 (-0.8, 0.0) vs 0.0 (-0.4, 1.3) in the placebo group, p=0.067). GEE results showed that the odds ratio (OR) for enthesiophyte progression in the secukinumab group was 0.264 (95% CI: 0.080-0.878, p=0.030), while the OR for partial erosion healing in the secukinumab group was 2.882 (95% CI: 1.130 to 7.349, p=0.027).

Conclusions:
Secukinumab demonstrates a potential benefit in facilitating partial erosion repair and preventing enthesiophyte progression in PsA.

Source: onlinelibrary.wiley.com

*Funding: Early view funding unknown.

Cosentyx (secukinumab)
Quote
« Next Oldest | Next Newest »


Possibly Related Threads…
Thread Author Replies Views Last Post
News Tremfya and liver fibrosis progression with psoriasis Fred 3 500 Sat-19-04-2025, 14:28 PM
Last Post: Kat
News Could c-reactive protein predict psoriatic arthritis Fred 7 1,131 Mon-07-04-2025, 13:15 PM
Last Post: Forest Walker
News Cosentyx and generalized pustular psoriasis Fred 2 569 Fri-04-04-2025, 16:53 PM
Last Post: Fred
News Treatment goals with psoriatic arthritis Fred 5 1,030 Thu-27-03-2025, 04:29 AM
Last Post: mataribot
News Circadian rhythms and psoriatic arthritis Fred 1 476 Mon-10-03-2025, 20:28 PM
Last Post: Caroline



Users browsing this thread: 2 Guest(s)
    About | Contact us | Login | Register | Home | Cookies/GDPR | RSS Syndication | Portal | Types Of Psoriasis | Psoriasis Score | Members Only Boards
    Copyright © 2010 - 2025 Psoriasis Club | All Rights Reserved | Founded May 2010 | Psoriasis Club Is Self Funded Without Sponsors Or Donations | Software by MyBB | Social
Linear Mode
Threaded Mode